In men aged ≥65 years with documented symptomatic hypogonadism, what are the benefits and risks of testosterone replacement therapy?

Testosterone Replacement in Older Men: Benefits and Risks

Testosterone replacement therapy should NOT be routinely offered to all older men with low testosterone levels, but may be considered on an individualized basis for men ≥65 years with consistently documented low testosterone (<275-300 ng/dL on two separate morning measurements) AND clinically significant symptoms, after explicit discussion of uncertain long-term risks and modest short-term benefits. 1, 2, 3

Who Should Be Considered for Treatment

The Endocrine Society and American College of Physicians guidelines converge on a selective approach:

• Confirmed biochemical hypogonadism: Two morning testosterone levels <275-300 ng/dL (though expert panels disagree on exact thresholds—some favor <200 ng/dL, others <300 ng/dL) 1, 2
• Clinically significant symptoms: Sexual dysfunction (decreased libido, erectile dysfunction), reduced energy, or depressive symptoms 3
• Exclude secondary causes: Screen for sleep apnea and hypoxia before initiating therapy 1, 2

Critical caveat: The FDA-approved indication is strictly for organic hypogonadism (testicular failure, pituitary/hypothalamic disease)—NOT for age-related decline alone 4. Off-label use for age-related low testosterone remains controversial.

Documented Benefits (Modest at Best)

The Testosterone Trials (2016), the highest-quality evidence in older men, demonstrated 5, 6:

Sexual Function

• Moderate improvement in sexual activity, desire, and erectile function (primary benefit)
• Effect size clinically meaningful but modest

Physical Function

• Minimal benefit: Only 20.5% vs 12.6% achieved ≥50m improvement in 6-minute walk distance (P=0.003)
• Small increases in lean body mass but inconsistent strength gains 1

Mood and Vitality

• Slight improvement in mood and depressive symptoms
• No significant benefit for vitality or energy levels (contradicting common expectations) 5

Bone Density

• Small-to-moderate increases in lumbar spine and hip bone mineral density 1, 7
• No proven fracture reduction: Recent TRAVERSE analysis showed NO fracture benefit and potentially higher fracture incidence (HR 1.43) 7

Metabolic Effects

• Improved hemoglobin/corrected anemia 5, 6
• Modest improvements in body composition (increased lean mass, decreased fat mass) 1

What Does NOT Improve

• Cognitive function 6, 8
• Walking distance/physical performance (inconsistent) 5
• Vitality (Functional Assessment of Chronic Illness Therapy-Fatigue scale showed no benefit) 5

Documented Risks and Harms

Cardiovascular Concerns

• TRAVERSE trial (most recent large study): No increase in major adverse cardiovascular events over 3-4 years 6, 8, 9
• However: Increased non-calcified coronary plaque volume (clinical significance uncertain) 6
• FDA warning (2025): Mild increase in systolic blood pressure noted 9
• Verdict: Neutral to possibly beneficial cardiovascular effect, but long-term safety beyond 4 years unknown 10

Prostate-Related

• Increased PSA levels and urological referrals 1, 6
• No proven increase in prostate cancer risk in short-term trials 11, 12
• Monitoring required: PSA and digital rectal exam before treatment, at 3 months, then per age-appropriate screening 1, 2

Hematologic

• Erythrocytosis: Common, especially with intramuscular formulations (up to 44% vs 3-18% with transdermal) 10
• Requires monitoring hematocrit at baseline, 3 months, then periodically 2

Musculoskeletal

• Tendon injury risk: Observational data suggest association (mechanism: rapid muscle gains outpace tendon adaptation) 7
• No fall prevention: Testosterone Trials showed no reduction in falls 7

Other Adverse Effects

• Testicular atrophy and infertility (common, usually reversible) 10
• Fluid retention (rarely clinically significant) 10
• Formulation-specific: Skin reactions with patches (up to 66%), minimal with gels (5%) 1, 10

Treatment Algorithm

Step 1: Confirm Diagnosis

• Two morning (before 10 AM) total testosterone measurements <275-300 ng/dL
• Document specific symptoms (sexual dysfunction most responsive)
• Measure LH/FSH to exclude primary testicular failure 9
• Screen for sleep apnea, chronic hypoxia 1, 2

Step 2: Baseline Risk Assessment

• Digital rectal exam + PSA (exclude if PSA >4.0 ng/mL or abnormal exam) 1
• Hematocrit (exclude if >50%) 2
• Blood pressure 9
• Cardiovascular risk stratification 9

Step 3: Initiate Treatment (If Appropriate)

• Preferred formulation: Intramuscular testosterone (enanthate/cypionate 75-100 mg weekly or 150-200 mg every 2 weeks)—lower cost, similar efficacy to transdermal 2, 3
• Alternative: Transdermal gel 5-10g daily (1% formulation) if patient prefers 2
• Target level: Mid-normal range (400-700 ng/dL) 2, 12

Step 4: Monitoring Schedule

• 3 months: Testosterone level, PSA, hematocrit, symptom response, blood pressure 2, 9
• 12 months: Reassess symptoms—discontinue if no improvement in sexual function 3
• Annually thereafter: PSA, hematocrit, symptom assessment, blood pressure 2

Step 5: Urological Referral Triggers

• PSA >4.0 ng/mL OR increase >1.4 ng/mL in any 12-month period 1, 2
• PSA velocity >0.4 ng/mL/year (if >2 years data) 1
• Abnormal digital rectal exam 1
• Prostate symptom score (AUA/IPSS) >19 1

Key Clinical Pitfalls

1. Treating asymptomatic men: No evidence supports treatment in men with low testosterone but no symptoms 1, 2

2. Expecting dramatic improvements: Benefits are modest; sexual function improves moderately, but energy/vitality often do not 5

3. Inadequate monitoring: Erythrocytosis and PSA elevation require systematic surveillance 1, 2

4. Ignoring cardiovascular risk factors: Blood pressure must be monitored given recent FDA warnings 9

5. Continuing ineffective treatment: If no symptom improvement by 12 months, discontinue 3

6. Wrong formulation choice: Intramuscular is cost-effective first-line; transdermal reserved for injection-averse patients 3

7. Overlooking fracture risk: Despite bone density improvements, fracture prevention is unproven and possibly increased 7

Evidence Quality and Limitations

The evidence base has significant limitations 1, 5:

• Most trials are 1-3 years duration (long-term effects unknown)
• Small sample sizes underpowered for cardiovascular events and prostate cancer
• Trials excluded high-risk men (limiting generalizability)
• No fracture outcome data despite bone density improvements
• Inconsistent testosterone thresholds across studies

The strongest recent evidence (Testosterone Trials, 2016) provides only low-to-moderate certainty for benefits and insufficient evidence for most harms 5, 6. The 2020 American College of Physicians guideline explicitly rates all recommendations as "conditional" with "low-certainty evidence" 3.

Bottom Line for Clinical Practice

Testosterone therapy in older men provides modest sexual function benefits but minimal improvements in other age-related symptoms. 5, 6 The decision requires explicit discussion that:

• Sexual function may improve moderately
• Energy, vitality, and physical function are unlikely to improve meaningfully
• Long-term cardiovascular and prostate safety remain uncertain
• Monitoring burden is substantial
• Treatment should be discontinued if ineffective by 12 months 3

This is NOT a fountain-of-youth intervention—it is a targeted therapy for specific symptoms in carefully selected men with confirmed biochemical hypogonadism. 1, 2, 3